Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 8,612 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: External Wounds Measured for Length by Width Using a Ruler
Interventions: "gold standard" LxW manual ruler measurement technique, WMMS ImageReview software's LxW measurement technique, WMMS ImageReview software's Visual External Wound Trace, WMMS ImageReview software's External Wound Trace Overlay; Device
Lead sponsor: Wound Vision; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Psoriasis, Arthritic
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more

Conditions: Cystic Fibrosis
Interventions: Lung T1 MRI; Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more

Conditions: Type II Diabetes Mellitus
Interventions: JTT-130, JTT-130 Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 48
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dexmedetomidine, Mechanical Ventilation Complication, Critically Ill
Interventions: Fentanyl, Dexmedetomidine; Drug
Lead sponsor: Duke University; Other
Eligibility: Up to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Little Rock, Arkansas • Gainesville, Florida • Indianapolis, Indiana + 15 more

Conditions: Carcinoma, Non-small-cell Lung
Interventions: TLK286 in combination with docetaxel; Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Houston, Texas

Conditions: Breast Cancer
Interventions: conventional surgery, Sentinel node resection followed by node examination; Procedure
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 5,611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2014
U.S. locations: 68
States / cities: Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 61 more

Conditions: Alcohol Consumption
Interventions: Placebo, 10 mg Obeticholic Acid (OCA); Drug
Lead sponsor: Suthat Liangpunsakul; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Insomnia, Insomnia Chronic, Insomnia, Primary, Sleep Disturbance, Sleep Disorder, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke, Autonomic Dysfunction, Systemic Inflammatory Response, Metabolic Disease
Interventions: Sleep Healthy Using The Internet (SHUTi), Telephonic CBT-I, Face-to-Face CBT-I, Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care; Behavioral · Other
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atrial Fibrillation
Interventions: Apixaban, Parenteral heparin and/or oral Vitamin K antagonist; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more

Conditions: Insomnia Disorder
Interventions: ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Upland, California • Brandon, Florida + 12 more

Conditions: Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 792
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more

Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 410
States / cities: Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Placebo; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more

Conditions: Endoscopic Ultrasound
Interventions: SuperNO2VA; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Psoriasis
Interventions: Placebo, 50 mg etanercept, 80 mg ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Heart Failure
Interventions: Left Ventricular Capture Management Software; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 18
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 15 more

Conditions: Acute Renal Failure
Interventions: renal replacement therapy; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 22
States / cities: No. Little Rock, Arkansas • San Francisco, California • West Los Angeles, California + 19 more

Conditions: Low Back Pain
Interventions: Buprenorphine transdermal system, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 86
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more

Search by objective public record fields.

Measuring Wounds Found on the Outside of the Body Surface

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

DOSE Trial of Opioid Sparing Effect

Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling

SHADES Mechanistic Trial

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Comparison of Oxygenation Between Nasal PAP vs Nasal During Propofol-based Sedation for EUS

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Left Ventricular Capture Management (LVCM) Software Download Clinical Trial

Acute Renal Failure Trial Network (ATN) Study

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain